Research output per year
Research output per year
Search results
-
2022
Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)
Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., Hong, D. S., Wang, J. S., Steidl, U., Walensky, L. D., Naik, G., Guerlavais, V., Vukovic, V., Annis, D. A., Aivado, M. & Meric-Bernstam, F., 15 Jan 2022, In: Clinical Cancer Research. 28, 2, p. 429 1 p.Research output: Contribution to journal › Comment/debate
Open Access4 Citations (Scopus) -
2017
Academic cancer center phase i program development
Frankel, A. E., Flaherty, K. T., Weiner, G. J., Chen, R., Azad, N. S., Pishvaian, M. J., Thompson, J. A., Taylor, M. H., Mahadevan, D., Lockhart, A. C., Vaishampayan, U. N., Berlin, J. D., Smith, D. C., Sarantopoulos, J., Riese, M., Saleh, M. N., Ahn, C. & Frenkel, E. P., Apr 2017, In: Oncologist. 22, 4, p. 369-374 6 p.Research output: Contribution to journal › Comment/debate
Open Access -
2013
Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study
Saleh, M. N., Bussel, J. B. & Cheng, G., 2013, In: Transfuze a Hematologie Dnes. 19, 2, p. 191 1 p.Research output: Contribution to journal › Comment/debate
2 Citations (Scopus) -
2011
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402))
Cheng, G., Saleh, M. N. & Marcher, C., 2011, In: The Lancet. 377, 9766, p. 640 1 p.Research output: Contribution to journal › Comment/debate
Open Access